Avanir's Diabetic Drug shows positive results on Trial
Avanir Pharmaceuticals shares climbed as the company reported today positive results of its large pharmacokinetic study to identify an alternative dosing formulation of Zenvia, designed to deliver similar efficacy as observed in the first Phase III clinical study in diabetic peripheral neuropathic pain.
Tax rebate deal could mean checks by MayToday the company said the new formulation of Zenvia will improve the cardiovascular risk profile since it offers a lower exposure to the pharmaceutical agent quinidine. In April 2007, Avanir announced successfully meeting all primary endpoints in a Phase III study of Zenvia in DPN pain.
Diabetic peripheral neuropathy pain affects 5 to 50% of people with diabetes in the United States, diminishing peripheral sensation gradually and eventually complete loss of sensation.
Shares of Avanir were last at $1.28 after jumping 4.20 percent at the closing trading on Nasdaq today, but an additional 2.97 percent increase was posted in after hours electronic trading.
- 1 Nomura CEO seeks change with Lehman buy
- 2 CE Donald Tsang meets UK Prime Minister in London
- 3 Macaus hot streak shows signs of cooling
- 4 Financials drag on market; Dow falls more than 240
- 5 Asia stocks sink as layoffs add to global gloom
- 6 Drop in Stock Market Sends Traders to the Safety of the U.S. Dollar
- 7 HSBC to cut 500 jobs in Asia as slump takes toll
- 1 HK typhoon alert No.1 issued
- 2 HSBC reports 1H fall in profit 29 percent
- 3 Bryant scores 19, helps US beat Russia in tuneup
- 4 Actor Morgan Freeman is injured in car accident
- 5 Jolie-Pitt baby twins photos online
- 6 Christina Applegate treated for breast cancer
- 7 Paris Hilton's mom takes offense at McCain's humor
|
- 1 China's Baidu.com fights to rescue reputation
- 2 Nomura CEO seeks change with Lehman buy
- 3 World Bank chief: Better ties with Russia a must
- 4 HSBC to cut 500 jobs in Asia as slump takes toll
- 5 SBI hiring amid global firing
- 6 Jerry Yang to step down as CEO as Yahoo looks to reinvent itself
- 7 Home Depot Expected to Report Loss, Similar to Lowe's and Target
|
|
